FTC Report Highlights PBM Dominance Over Drug Market

Tuesday, 9 July 2024, 12:48

The recent Federal Trade Commission (FTC) report uncovered that Pharmacy Benefit Managers (PBMs) are prioritizing profits over patient care and the sustainability of independent pharmacies. The report emphasizes the extensive control PBMs have in determining drug availability, pricing, and accessibility to different medications. This revelation sheds light on the negative impact these practices have on patients and small pharmacies, raising concerns about the need for regulatory oversight and fair competition within the pharmaceutical industry.

Statnews — FTC Report Highlights PBM Dominance Over Drug Market

FTC Report on PBM Practices

Key Findings:

PBMs prioritize profits over patient welfare
Control over drug availability and pricing
Impact on independent pharmacies and patient access

The Federal Trade Commission's report released on Tuesday highlighted the concerning dominance of Pharmacy Benefit Managers (PBMs) in the pharmaceutical market. The report revealed how PBMs prioritize profit margins at the expense of patient care and independent pharmacies. By exerting significant control over drug availability and pricing, PBMs have raised serious questions about fair competition and patient access to essential medications.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.